MK-677 (Ibutamoren) Month-by-Month: What Actually Happens in the First 3 Months

What Is MK-677 and Why Are Women Using It?

MK-677 is an orally active, non-peptide ghrelin receptor agonist. It stimulates the pituitary to release growth hormone (GH) and raises insulin-like growth factor 1 (IGF-1) without requiring injections. That oral convenience is a large part of its appeal.

Women across reproductive years, perimenopause, and post-menopause are turning to it for a short list of reasons: lean mass preservation, faster recovery, better sleep, skin thickness, and hair quality. Some women with polycystic ovary syndrome (PCOS) use it hoping to counteract the metabolic sluggishness that comes with insulin resistance, though that is a real irony given MK-677's own effect on insulin sensitivity (more on that below).

The compound is not a selective androgen receptor modulator (SARM), despite being sold alongside SARMs in research-chemical markets. The mechanism is different. Still, the regulatory status is the same: it is not approved by the FDA for any indication in any population.

The GH Axis in Women vs. Men

Women already have a more active GH pulse pattern than men across reproductive life. Estrogen amplifies pituitary GH release, which means GH axis responsiveness in pre-menopausal women differs meaningfully from the male populations most studied in MK-677 trials. At menopause, GH pulse amplitude and IGF-1 fall alongside estrogen, which is part of why post-menopausal women show up in some of the small trials examining GH secretagogues.

The Evidence Gap Women Deserve to Know About

Most published MK-677 clinical data comes from trials in older men or mixed elderly cohorts. A 2008 JAMA study by Nass et al. enrolled 65 adults aged 60 to 81 years and found that 25 mg daily raised IGF-1 by approximately 84 percent but also increased fasting glucose and insulin. The sex-disaggregated subgroup was too small to draw firm female-specific conclusions. Dedicated trials in reproductive-age women, women with PCOS, or perimenopausal women do not exist in the published literature as of early 2025. What follows combines the available trial data with synthesized user experiences. Where data is extrapolated from male or elderly cohorts, that is stated plainly.

Month 1: What Women Actually Report in the First Four Weeks

The first month is largely about sleep, appetite, and water. Body composition changes are minimal this early, which surprises many first-time users.

Sleep Changes (Week 1 to 2)

The most consistent early effect is a shift in sleep architecture. MK-677 increases slow-wave (deep) sleep, which is where GH pulses naturally peak. A randomized trial by Copinschi et al. showed that ibutamoren significantly increased stage IV sleep in young adults within the first two weeks at doses of 25 mg. Women on forums and Drugs.com reviews frequently describe this as "vivid, heavy dreams" and waking feeling unusually rested, though a subset report the opposite: disrupted sleep and restlessness, especially at higher doses taken in the evening.

Practical note: taking MK-677 at night, 30 to 60 minutes before bed, appears to align the GH pulse with natural nocturnal GH release and may reduce daytime drowsiness, a common Month 1 complaint.

Appetite and Ghrelin Effects in Women

Ghrelin is the hunger hormone. MK-677 mimics it. Expect a meaningful increase in appetite, often starting within 48 to 72 hours. For women using MK-677 for lean mass gain, this is a feature. For women using it for fat loss or weight management, this is the first serious friction point.

Women in perimenopause already contend with appetite dysregulation tied to fluctuating estrogen and progesterone. Adding a ghrelin agonist on top of that hormonal backdrop may amplify hunger more than the male-derived trial data would predict. This is extrapolated from mechanistic data, not a directly studied outcome in perimenopausal women.

Water Retention: More Pronounced in Women

GH raises sodium retention through the kidney. Water retention in the hands, feet, and face is one of the most common Month 1 complaints in women's accounts. This tends to show up on the scale as a 1 to 3 kg apparent "gain" that has nothing to do with fat or muscle. It resolves in most users by Week 6 to 8 as the body equilibrates, or when dose is lowered.

Women with cyclical bloating (premenstrual water retention) may find Month 1 on MK-677 particularly uncomfortable in the luteal phase. Lowering dose to 10 mg during the late luteal phase is a strategy some women describe anecdotally; no clinical trial has tested this.

Insulin Sensitivity: The PCOS Concern

Nass et al. (JAMA, 2008) reported a statistically significant increase in fasting glucose (mean increase approximately 0.3 mmol/L) and insulin in the MK-677 arm after 12 months. Women with PCOS already carry elevated baseline insulin resistance. Using a compound that further blunts insulin sensitivity is a real metabolic risk that deserves a direct conversation with a clinician before starting.

Month 2: IGF-1 Rising, First Body Composition Signals

Month 2 is where the physiology starts to show up in the mirror and in lab work, though still subtly.

IGF-1 Elevation

IGF-1 typically peaks by Week 4 to 6 and stays elevated as long as dosing continues. In the Nass et al. Trial, participants on 25 mg daily reached IGF-1 levels approximately 84% above baseline by the end of the study period. Women's baseline IGF-1 is estrogen-dependent and declines after menopause. A post-menopausal woman on MK-677 may see a larger relative IGF-1 rise compared to a pre-menopausal woman whose IGF-1 is already well-supported by endogenous estrogen. Whether that larger rise is clinically beneficial or carries more risk is unknown.

Muscle and Strength: Early Signals

Most women do not see significant lean mass changes until at least 8 weeks. What Month 2 often delivers is improved training recovery, less muscle soreness, and slightly better neuromuscular performance during resistance training sessions. This aligns with GH's role in protein synthesis and collagen turnover.

Skin and Hair: What the Data and Reports Say

Women's accounts show a consistent pattern that the published trial data does not directly measure. Here is a framework for interpreting what is GH-mediated versus what is placebo-driven, organized by the three tissue types women most commonly report on:

Skin thickness and texture. GH stimulates dermal collagen production. A 1996 trial by Johannsson et al. in GH-deficient adults showed increased skin thickness with GH therapy. MK-677 raises GH indirectly; skin changes at Month 2 are plausible but not directly proven in women using MK-677 specifically.

Hair quality. GH and IGF-1 support hair follicle cycling. Women in post-menopause and those with female-pattern hair loss report improved hair thickness by Month 2 to 3. This is entirely anecdotal and extrapolated from GH physiology. No MK-677 trial has measured hair outcomes in women.

Nail growth. Fast-growing nails are one of the more consistent reports in Month 2. This is consistent with GH/IGF-1 biology and is not life-stage specific.

Prolactin: A Signal Women Should Not Ignore

Some users and a subset of clinical reports note elevated prolactin on MK-677. Ghrelin receptor activation can stimulate prolactin release through pathways partly independent of GH. Elevated prolactin disrupts the menstrual cycle, suppresses ovulation, and can cause galactorrhea. Any woman who notices missed periods, nipple discharge, or libido changes during Month 2 should stop MK-677 and check a prolactin level before continuing.

Month 3: Body Composition Changes Become Measurable

By Month 3, the changes that brought most women to MK-677 in the first place are either present or clearly absent.

Lean Mass and Fat Mass

A 12-week randomized trial by Murphy et al. in 32 older adults showed that 25 mg MK-677 daily produced a statistically significant increase in lean mass (mean 1.6 kg) and fat mass also increased modestly, consistent with GH's effects on appetite and nutrient partitioning. The fat mass increase is a less-discussed finding that matters for women using MK-677 primarily for body composition.

Pre-menopausal women using MK-677 alongside structured resistance training report the most positive body composition outcomes at the 3-month mark. Women using it without a training stimulus report appetite-driven weight gain more often.

Bone Density: Relevant Across Life Stages

GH secretagogues increase bone turnover markers. A trial by Svensson et al. showed that two years of MK-677 at 25 mg increased bone mineral density markers in elderly adults. Three months is too short to see DXA-measurable bone density changes, but the bone remodeling signal is present. For post-menopausal women managing osteopenia or osteoporosis, this is mechanistically interesting but not yet supported by data strong enough to use MK-677 as a bone therapy.

Cognitive and Mood Effects

Some women report sharper recall, improved mood, and better verbal fluency by Month 3. IGF-1 crosses the blood-brain barrier and has neurotrophic properties. This is biologically plausible but not tested in women with MK-677 specifically. The evidence is extrapolated from GH replacement studies in GH-deficient adults.

When Month 3 Disappoints

Not every woman sees meaningful change. Factors that predict a poor response include:

• Baseline IGF-1 already in the upper quartile for age (GH axis has less room to amplify)
• Insufficient caloric protein intake to support GH-driven anabolism
• Uncontrolled insulin resistance (PCOS, pre-diabetes) blunting the IGF-1 response
• Dose too low (10 mg vs 25 mg shows a dose-response relationship in available trials)
• Concurrent use of compounds that suppress GH release (some SSRIs, high-dose glucocorticoids)

Pregnancy, Lactation, and Contraception

MK-677 is contraindicated in pregnancy. There are no human pregnancy safety data. Animal reproductive toxicity studies have not been published in peer-reviewed literature accessible to clinicians, and the compound has never progressed through FDA review for any indication. Given that IGF-1 elevation drives cellular proliferation, the theoretical risks to embryonic and fetal development are sufficient reason to avoid it entirely during pregnancy.

If you are trying to conceive, stop MK-677 before attempting conception. There is no established washout period from clinical data. A conservative approach of stopping at least 4 to 6 weeks before a conception attempt is reasonable, based on the compound's half-life of approximately 24 hours and the lack of known teratogen registry data.

Lactation: MK-677 transfer to breast milk has not been studied. Given the oral bioavailability and lipophilicity of the compound, transfer to milk is pharmacokinetically plausible. Avoid during breastfeeding.

Contraception: Women of reproductive age using MK-677 should use reliable contraception. If MK-677 raises prolactin sufficiently to suppress ovulation (see Month 2 section), that is not a reliable contraceptive mechanism and should not be treated as one. Use a separately verified contraceptive method.

Hormonal contraceptives and MK-677: Estrogen-containing contraceptives raise IGF-1 binding proteins and may blunt the free IGF-1 rise from MK-677. This interaction has not been directly studied but is mechanistically supported by the known relationship between oral estrogen and IGF-1 bioavailability.

Who This May Be Right For and Who Should Avoid It

Potentially Lower-Risk Candidates (with medical supervision)

Post-menopausal women with documented low IGF-1, muscle loss disproportionate to aging norms, or poor sleep architecture are the population closest to the clinical trials that exist. This does not mean MK-677 is approved or recommended for them; it means the available data is at least somewhat applicable.

Women in late perimenopause with significant GH axis decline and no PCOS, no insulin resistance, no active cancer history, and no hyperprolactinemia represent a similarly reasonable candidate profile for supervised use.

Women Who Should Avoid MK-677

• Pregnant or planning pregnancy in the near term
• Breastfeeding
• Any personal or first-degree family history of estrogen-receptor-positive or IGF-1-sensitive cancers (breast, endometrial, ovarian). IGF-1 is a mitogenic signal; elevated circulating IGF-1 is associated with increased breast cancer risk in pre-menopausal women.
• Active PCOS with insulin resistance and elevated fasting insulin
• Hyperprolactinemia or prolactinoma
• Type 2 diabetes or pre-diabetes
• Edema-prone conditions (heart failure, chronic kidney disease, lymphedema)
• Active eating disorder with restriction, as appetite amplification adds risk

Life-Stage Summary Table

| Life Stage | Key Concern | Evidence Status | |---|---|---| | Reproductive years | Cycle disruption, prolactin, pregnancy risk | No direct trials | | Trying to conceive | Contraindicated; stop before conception attempt | No human data | | Pregnancy | Contraindicated | No human data | | Postpartum / lactating | Avoid; milk transfer unknown | No data | | Perimenopause | Appetite, insulin resistance, water retention | Extrapolated | | Post-menopause | Closest to studied population; bone and lean mass signal | Small RCTs in elderly |

Dosing Patterns Women Report and What the Trials Used

The dose range in published trials is 10 mg to 25 mg orally once daily. The Murphy et al. Trial used 25 mg. Nass et al. used 25 mg over 12 months.

Women in forums and review sites most commonly report starting at 10 mg to 12.5 mg to assess tolerance, particularly for sleep disturbance and water retention, then increasing to 25 mg by Week 3 to 4 if tolerated. A subset stays at 10 mg long-term, citing that a lower dose provides 70 to 80 percent of the sleep and recovery benefit with meaningfully less bloating and appetite stimulation.

Cycling (8 to 12 weeks on, 4 weeks off) is a common practice in user communities. No clinical data supports a specific cycle protocol for women. The rationale offered is reducing desensitization of the ghrelin receptor, though this has not been demonstrated in human studies.

Baseline and follow-up IGF-1 testing is the most clinically useful monitoring tool. A target IGF-1 in the age-matched upper-normal range (not supraphysiologic) is a practical guardrail. Fasting glucose and fasting insulin should be checked at baseline and at 6 to 8 weeks given the glucose-blunting effect documented in trials.

"Does MK-677 Work?" The Honest Answer for Women

MK-677 raises IGF-1. That is documented. The Nass et al. JAMA trial confirms it. Whether that IGF-1 rise translates into meaningful, durable improvements in the outcomes women care about depends heavily on life stage, hormonal background, training load, protein intake, and baseline metabolic health.

Two direct quotations from the clinical literature are worth placing here.

The Nass et al. Study authors wrote: "MK-677 increased growth hormone and IGF-I levels to those of healthy young adults... However, it also increased fasting blood glucose and insulin resistance." This dual finding does not disappear because a compound is taken orally rather than injected.

The FDA's consumer advisory on unapproved growth hormone secretagogues states that products marketed as "research chemicals" are not evaluated for safety or efficacy and that consumers "have no way of knowing if these products are safe."

Women have been substantially under-represented in the small clinical trial base that exists for MK-677. What is known comes mostly from older men and elderly mixed-sex cohorts. Extrapolating those findings to a 38-year-old woman in perimenopause or a 28-year-old woman with PCOS requires clinical judgment, honest uncertainty, and ideally, physician oversight with laboratory monitoring.